Skip to content

Compare the Efficacy and Safety of Finerenone, a New Type of Mineralocorticoid Receptor Antagonist, and Spironolactone in the Treatment of Primary Aldosteronism: a Single-Center, Prospective, Randomized Controlled Study

Compare the Efficacy and Safety of Finerenone, a New Type of Mineralocorticoid Receptor Antagonist, and Spironolactone in the Treatment of Primary Aldosteronism: a Single-Center, Prospective, Randomized Controlled Study - Compare the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069660
Enrollment
Unknown
Registered
2023-03-22
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Aldosteronism

Interventions

Sponsors

Drum Tower Hospital Affiliated to Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18-75 years old. 2.History of hypertension, DBP = 2.5 mmol/L. 4.Primary Aldosteronis diagnosed by increased aldosterone renin ratio (ARR) > 30 ng/dl: ng/ml/h, and serum aldosterone levels >=15 ng/dl, and confirmed by captopril inhibition test.

Exclusion criteria

Exclusion criteria: 1. Abnormal renal function: serum creatinine >= 2*ULN or eGFR 2.5*ULN, TBIL > 1.5*ULN 3. Cardiac insufficiency, acute myocardial infarction, stroke or other acute cardiovascular events within 6 months; 4. Take spironolactone, guanethidine or reserpine 30 days before enrollment; 5. Known or suspected tumor; Other autoimmune diseases, uncontrolled infectious diseases, serious respiratory, blood and nervous system diseases; 6. There is a pregnancy plan in pregnancy or 3 months before and after treatment. Breast-feeding women; 7. Those who have mental illness, alcohol or drug abuse and cannot cooperate with treatment.

Design outcomes

Secondary

MeasureTime frame
aldosterone to renin ratio;

Primary

MeasureTime frame
Blood pressure;Serum potassium;Plasma renin activity;

Countries

China

Contacts

Public ContactPing Li

Drum Tower Hospital Affiliated to Nanjing University Medical School

li78321@yeah.net+86 25 83106666 61431

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026